Navigation Links
Isis Pharmaceuticals to Present at the Roth 23rd Annual OC Growth Stock Conference
Date:3/7/2011

CARLSBAD, Calif., March 7, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at Roth's 23rd Annual OC Growth Stock Conference on Monday, March 14, 2011 at 1:00 p.m. PT at the Ritz Carlton Laguna Niguel.  

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com.  A replay of the presentation will be available on the Isis Web site within 48 hours and will be archived for a limited time.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners.  The Company has successfully commercialized the world's first antisense drug and has 24 drugs in development.  Isis' drug development programs are focused on treating cardiovascular, metabolic, and severe neurodegenerative diseases and cancer.  Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases.  Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics.  Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing.  As an innovator in RNA-based drug discovery and development, Isis has designed and executed a patent strategy that has provided the Company with strong and extensive protection for Isis' drugs and technology.  Additional information about Isis is available at www.isispharm.com.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Keryx Biopharmaceuticals Announces Oral Presentation of Final Zerenex™ Short-Term Phase 3 Data at the Upcoming National Kidney Foundations 2011 Spring Clinical Meetings
2. Aerie Pharmaceuticals Completes $30 Million Series B Financing to Fund Further Development of Innovative Glaucoma Product Portfolio
3. Questcor Pharmaceuticals Selects BDO USA as its Auditor
4. Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results
5. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2010 Financial Results
6. Endo Pharmaceuticals Launches FORTESTA™ (Testosterone) Gel for Topical Use Class III for Adult Men in the U.S. With Low Testosterone
7. Inovio Pharmaceuticals to Present at ROTH 23rd Annual Growth Stock Conference
8. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the Cowen and Company 31st Annual Health Care Conference in Boston on March 9, 2011
9. Onyx Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
10. Savient Pharmaceuticals to Present at the 31st Annual Cowen & Co. Health Care Conference
11. Accumetrics Signs Development & Supply Agreement With Portola Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... India , April 29, 2016 ... Pipeline Review, H1 2016" market research report that ... complete with comparative analysis at various stages, therapeutics ... route of administration (RoA) and molecule type, along ... releases. It also reviews key players involved in ...
(Date:4/29/2016)... , April 29, 2016 /PRNewswire/ ... Contamine, Directeur Financier Sanofi, ... santé, publie ses résultats pour le ... du Groupe, Jérôme Contamine, commente les ... et les perspectives pour le reste ...
(Date:4/29/2016)... India , April 29, 2016 ... the life science laboratory due to the growing demands ... by advance technology, contemporary automated systems are already adept ... performed by slow, tedious and manual labor. Instrumentation continues ... were not even conceivable just a few years ago. ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... May 04, 2016 , ... Mediware Information ... therapy software application that helps blood and marrow transplant (BMT) programs meet compliance ... launch, Mediware has continued to enhance core application features. These enhancements are designed ...
(Date:5/4/2016)... ... May 04, 2016 , ... International Conference on Obesity and ... 2016 at Las Vegas. It aims to bring together academicians, scientists, dietitians, surgeons, ... organizations across the globe; making the conference a perfect platform to share experience ...
(Date:5/3/2016)... (PRWEB) , ... May 04, 2016 , ... The ... 2016-2017 inductee into its VIP Woman of the Year Circle. She is recognized with ... exclusively for professional women, boasting more than 850,000 members and over 200 operating Local ...
(Date:5/3/2016)... , ... May 03, 2016 , ... Sue Desmond-Hellmann, chief ... of 2016 to stretch the limits of human possibility in her keynote address at ... in the Georgia Dome. , Drawing on her rich experience as a scientist, physician ...
(Date:5/3/2016)... ... May 03, 2016 , ... With the opioid epidemic now ... excessive levels of alcohol use. Alcohol and its misuse causes long-term consequences for ... the susceptibility to strokes in those 65 years and older. In addition, there ...
Breaking Medicine News(10 mins):